India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.
According to sources in the local medtech industry, India’s drug pricing body, the National Pharmaceutical Pricing Authority, requested a few...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?